

Qty: 100 μg/400 μl Rabbit anti-VEGI Catalog No. 34-3900 Lot No. See product label

Rabbit anti-VEGI

FORM

This polyclonal antibody is supplied as a 400 µl aliquot at a concentration of 0.25 mg/ml in phosphate buffered saline (pH 7.4) containing 0.1% sodium azide. The antibody is epitope-affinity-purified from rabbit antiserum.

PAD: ZMD.58

IMMUNOGEN

Synthetic peptide derived from the C-terminal sequence of human VEGI.

SPECIFICITY

This antibody reacts with the ~20kDa human VEGI protein.

REACTIVITY

Reactivity is confirmed with human PC-3 prostate adenocarcinoma cell lysates.

Sample	Western Blotting	ELISA
Human	+++	ND
Immunogen	NA	+++

(Excellent +++, Good++, Poor +, No reactivity 0, Not applicable NA, Not determined ND)

USAGE

Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

ELISA: $0.1-1.0 \mu g/ml$ **Western Blotting:** $1-2 \mu g/ml$

STORAGE

Store at 2-8°C for up to one month. Store at -20°C for long term storage. Avoid repeated freezing and thawing.

(cont'd)

BACKGROUND

Vascular endothelial growth inhibitor (VEGI) belongs to the human tumor necrosis factor (TNF) family and acts as a multifunctional cytokine. VEGI is expressed predominantly in endothelial cells and is an endothelial cell-specific negative regulator of angiogenesis. Human VEGI protein contains 174 amino acids. The calculated molecular weight is approximately 20kDa. An experiment examining *in vitro* transcription and translation involving the use of a cDNA clone as a template revealed a similar molecular weight of approximately 22kDa. Hydrophobicity analysis predicts a 13 amino acid hydrophobic region that follows the C-terminal segment of 12 residues; this is typical of a type II transmembrane protein with the C-terminus on the extracellular surface, a single transmembrane domain, and a short cytoplasmic tail. Northern blots reveal that VEGI transcripts have been observed in the endothelial cells of placenta, lung, kidney, skeletal muscle, pancreas, spleen, prostate, small intestine, and colon.

REFERENCES

- 1. Haridas V, et al. VEGI, a new member of the TNF family, activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18(47): 6496-6504, (1999).
- 2. Zhai Y, et al. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer. 82(1): 131-136, (1999).
- 3. Zhai Y, et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 13(1): 181-189, (1999).

RELATED PRODUCTS

Product	Clone/PAD*	Cat. No.
Mouse anti-CD34	BI-3C5	18-0227
Rabbit anti-VEGF	Z-CVF3	18-0254
Rabbit anti-VEGF-C	Z-CVC7	18-2255
Rabbit anti-VEGF-C (propeptide)	ZMD.83	34-4300
PolyFast™ Rabbit anti-Neuropilin-1 + Peptide	Z-CN1	52-0107
PolyFast™ Rabbit anti-Neuropilin-2 + Peptide	Z-CN2	52-0207
Protein A	Sepharose [®] 4B	10-1041
rec-Protein G	Sepharose [®] 4B	10-1241

^{*}PAD: Polyclonal Antibody Designation

	ZyMAX™ Goat x Rabbit IgG	ZyMAX™ Goat x Mouse IgG
Conjugate	(H+L)	(H+L)
Purified	81-6100	81-6500
FITC	81-6111	81-6511
TRITC	81-6114	81-6514
Су™3	81-6115	81-6515
Cy™5	81-6116	81-6516
HRP	81-6120	81-6520
AP	81-6122	81-6522
Biotin	81-6140	81-6540

Zymed[®] and ZyMAX[™] are trademarks of Zymed Laboratories Inc. Cy[™] is a trademark of Amersham Life Sciences, Inc. Sepharose[®] is a registered trademark of Pharmacia LKB.

For Research Use Only